TCG Advisory Services LLC Has $526,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

TCG Advisory Services LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 28.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 6,494 shares of the biopharmaceutical company’s stock after purchasing an additional 1,433 shares during the period. TCG Advisory Services LLC’s holdings in Gilead Sciences were worth $526,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Nilsine Partners LLC boosted its position in Gilead Sciences by 1.1% during the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after acquiring an additional 127 shares during the last quarter. Etesian Wealth Advisors Inc. boosted its position in shares of Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after purchasing an additional 128 shares in the last quarter. Financial Counselors Inc. grew its stake in Gilead Sciences by 1.5% during the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares during the period. Revolve Wealth Partners LLC increased its holdings in Gilead Sciences by 3.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares in the last quarter. Finally, Institutional & Family Asset Management LLC lifted its stake in Gilead Sciences by 10.3% in the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 140 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several research analyst reports. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a research note on Wednesday, April 24th. Wells Fargo & Company dropped their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. Barclays decreased their target price on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Mizuho cut their price target on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Stock Down 0.8 %

NASDAQ:GILD traded down $0.55 on Friday, hitting $64.78. The stock had a trading volume of 7,822,720 shares, compared to its average volume of 7,345,331. Gilead Sciences, Inc. has a 1 year low of $64.33 and a 1 year high of $87.86. The firm’s fifty day simple moving average is $70.55 and its two-hundred day simple moving average is $75.78. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98. The stock has a market cap of $80.66 billion, a P/E ratio of 179.94, a price-to-earnings-growth ratio of 1.30 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same period last year, the business posted $1.37 earnings per share. Gilead Sciences’s revenue was up 5.3% on a year-over-year basis. Analysts predict that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.75%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.